CTLA4 and neoplasm: The successful co-targeting of PD-1 and CTLA-4 and encouraging results obtained in preclinical models that combined PD-1 antibodies with other immune checkpoint inhibitors has fostered strategies to combine immune checkpoint inhibitors to enhance anti-tumor responses in patients with cancer.